STOCK TITAN
  1. Home
  2. Sec-filings
  3. RZLT
  4. [8-K] Rezolute, Inc. Reports Material Event

[8-K] Rezolute, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock RZLT logo
Rezolute Inc

NASDAQ:RZLT

RZLT Rankings

#5702 Ranked by Market Cap
N/A Ranked by Dividends

RZLT Latest News

Jul 9, 2025
Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025)
May 28, 2025
Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism
May 13, 2025
Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update
May 5, 2025
Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
May 1, 2025
Rezolute to Participate in Upcoming Investor Conferences

RZLT Latest SEC Filings

Jul 17, 2025
[S-3] Rezolute, Inc. Shelf Registration Statement
Jun 26, 2025
[Form 4] Rezolute, Inc. Insider Trading Activity
Jun 24, 2025
[Form 4] Rezolute, Inc. Insider Trading Activity
Jun 23, 2025
[Form 4] Rezolute, Inc. Insider Trading Activity
Jun 23, 2025
[Form 4] Rezolute, Inc. Insider Trading Activity

RZLT Stock Data

455.78M
78.35M
13.48%
81.95%
3.57%
Biotechnology
Pharmaceutical Preparations
Link
United States
REDWOOD CITY